631,465 Shares in Biomea Fusion, Inc. $BMEA Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Posted by Stanley Muller on May 22nd, 2026

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 631,465 shares of the company’s stock, valued at approximately $783,000.

Other large investors have also bought and sold shares of the company. Scientech Research LLC purchased a new position in Biomea Fusion during the 3rd quarter worth $25,000. Engineers Gate Manager LP purchased a new stake in shares of Biomea Fusion in the second quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Biomea Fusion during the third quarter valued at about $32,000. Virtu Financial LLC bought a new position in shares of Biomea Fusion during the third quarter valued at about $39,000. Finally, Bridgeway Capital Management LLC boosted its holdings in Biomea Fusion by 99.2% during the second quarter. Bridgeway Capital Management LLC now owns 70,300 shares of the company’s stock worth $127,000 after purchasing an additional 35,000 shares during the last quarter. 96.72% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BMEA shares. Citigroup assumed coverage on shares of Biomea Fusion in a research report on Tuesday, May 5th. They issued an “outperform” rating for the company. D. Boral Capital restated a “buy” rating and issued a $12.00 target price on shares of Biomea Fusion in a research note on Tuesday, April 28th. Citizens Jmp initiated coverage on Biomea Fusion in a report on Tuesday, May 5th. They issued a “market outperform” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biomea Fusion in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded Biomea Fusion from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Biomea Fusion currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Read Our Latest Analysis on Biomea Fusion

Biomea Fusion Stock Performance

NASDAQ BMEA opened at $1.37 on Friday. The company has a market capitalization of $99.05 million, a PE ratio of -2.01 and a beta of -0.32. Biomea Fusion, Inc. has a 52-week low of $0.87 and a 52-week high of $3.08. The company has a 50-day simple moving average of $1.54 and a 200 day simple moving average of $1.38.

Biomea Fusion (NASDAQ:BMEA – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. As a group, analysts forecast that Biomea Fusion, Inc. will post -0.82 EPS for the current fiscal year.

Biomea Fusion Profile

(Free Report)

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.